These new immunotherapeutic approaches, such as immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD-1/PD-L1, have demonstrated clinical efficacy in a wide variety of solid tumors (4, 5) and have highlighted the critical role that the immune system plays in fighting cancer. This evidence concerns the gene CD274 and cancer.